In the absence of upfront NGS availability, we suggest starting with KRAS analysis, followed by BRAF and MSI testing in KRAS wild-type cases, thus promoting an efficient molecular classification strategy for CRC. This evidence concerns the gene BRAF and colorectal carcinoma.